FDA uses back door to restrict DTE compounding
In a Sep 16 letter to NABP CEO Al Carter, FDA states that DTE products “can put patients at harm” and that “therapies containing DTE are biological products subject to licensure under Section 351(i) of the PHS Act.”
IMPORTANT STAKEHOLDER BRIEFING: Measuring Patient Outcomes
If patient-reported outcomes can prove your value, why aren’t more of you collecting them?
URGENT: Deadline for joint Congressional letter on GFI 256 is September 30
One result of last week’s Compounders on Capitol Hill visits has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding
Push back against TRICARE network exclusion
Express Scripts (ESI) has slashed pharmacy reimbursements for 2023, making it impossible for many independent community pharmacies to participate in the TRICARE pharmacy network.
For PFMs: Protection from legal exposure
What if APC gave you a tool that would meet state and accreditation requirements that you have a continuous quality improvement program?
URGENT CALL TO ACTION: Ask your U.S. Representative to sign this joint Congressional letter on GFI 256!
One result of last week’s Compounders on Capitol Hill has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding,
A.J. Day receives APC’s Malmberg Award
A.J. Day, vice president of clinical services at PCCA, and an APC Board member, was named APC’s 2022 George and Lucy Malmberg Compounding Advocacy Champion during Compounders on Capitol Hill.
APC 2022 Fellows inducted
Please join us in congratulating the 2022 APC Fellows...